TheEdgeResearch
Home / Stocks / MRVI

Maravai LifeSciences Holdings, Inc. (MRVI)

NASDAQ Healthcare Biotechnology
$5.79 ▼ -0.43%
Market Cap
$1.60B
Sector
Healthcare
Industry
Biotechnology
Beta
0.58
52-Wk Range
2.28-7.44
CEO
Bernd Brust
Country
US
Currency
USD

Maravai LifeSciences Holdings, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Diego, CA, US. The stock last traded at $5.79, down 0.43% on the session, giving a market capitalisation of $1.60B. On trailing twelve-month figures it carries a trailing P/E of -10.80, a net margin of -37.1%. Its beta of 0.58 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-10.80
Price / Sales
7.65
Price / Book
4.18
EV / EBITDA
-29.80
Gross margin
34.6%
Operating margin
46.0%
Net margin
-37.1%
Return on equity
Debt / equity
0.86
Current ratio
4.05
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
435
IPO date
2020-11-20
Headquarters
San Diego, CA, US
About Maravai LifeSciences Holdings, Inc.

Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.

Comparable companies

Maravai LifeSciences Holdings, Inc. is most often compared with the following Healthcare names:

BCAXDNAIOVAKURALENZPRMEREPLSEPNTYRAVIR
More research on MRVI
MRVI technical analysis MRVI TheEdge Score Compare against peers
Open full interactive analysis & DCF →